Breaking news

SAP Surpasses Novo Nordisk To Become Europe’s Largest Company

SAP, the German software company, has officially overtaken Danish pharmaceutical giant Novo Nordisk to become Europe’s largest company by market capitalization. SAP’s market value reached $340 billion, surpassing Novo Nordisk’s $293.06 billion.

Key Factors Behind SAP’s Rise

SAP has experienced significant stock growth, particularly driven by optimism around its cloud business and its investments in generative artificial intelligence (AI). Since the start of 2025, SAP’s shares have risen 7%, and the company has seen a total return of 160% since the end of 2022, substantially outpacing the broader European STOXX 600 index, which rose by only 28%. The company’s increasing focus on cloud technologies and AI solutions for business applications has positioned it as a leader in digital transformation.

In recent months, strong investor interest has further propelled SAP’s growth, spurred by its expanding cloud services portfolio, AI developments, and strategic partnerships with large international corporations. These factors, alongside improvements to SAP’s ERP systems, have helped the company secure its top position.

Challenges For Novo Nordisk

In contrast, Novo Nordisk, which held the title of Europe’s largest company as recently as September 2023, has seen its stock lag due to disappointing results from its experimental obesity drug, Cagrisema. This has led to a slight decline in its market value, despite its strong performance in the pharmaceutical industry.

What This Means For The Future

The rise of SAP highlights the growing dominance of the technology sector in Europe, with digital transformation and AI solutions becoming key areas of investor focus. While Novo Nordisk is likely to remain a major player in the pharmaceutical industry, SAP’s success suggests that the European technology sector could experience even more growth, particularly with the increasing importance of AI and automation in business.

Looking ahead, competition between tech giants such as SAP and ASML is expected to intensify, marking the beginning of a new era for Europe’s technology-driven economy.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Aretilaw firm
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter